TABLE 94 Summary results for the sensitivity analyses for direct meta-analysis (HR, 95% Cl) for PFS/TTP comparing chemotherapy vs chemotherapy in population 2: population with non-squamous disease

Reference treatment vs comparator	Meta-analysis 1 (n = 16), HR (95% Cl)	Meta-analysis A (<i>n</i> = 15), HR (95% CI)	Meta-analysis B (n = 16), HR (95% CI)	Meta-analysis C (<i>n</i> = 16), HR (95% Cl)
GEM + PLAT vs VNB + PLAT ^{43,45,49,50,54,58}	1.06 (0.93 to 1.20)	1.06 (0.93 to 1.20)	1.06 (0.93 to 1.20)	1.06 (0.93 to 1.20)
GEM + PLAT vs PAX + PLAT ^{43,46,47,56,60}	1.05 (0.96 to 1.15)	1.05 (0.96 to 1.15)	1.08 (0.97 to 1.21)	1.05 (0.96 to 1.15)
$GEM + PLAT \text{ vs } DOC + PLAT^{47}$	0.87 (0.73 to 1.04)	0.87 (0.73 to 1.04)	0.87 (0.73 to 1.04)	0.87 (0.73 to 1.04)
$GEM + PLAT \text{ vs } PEM + PLAT^{61}$	0.90 (0.79 to 1.02)	0.90 (0.79 to 1.02)	0.90 (0.79 to 1.02)	0.90 (0.79 to 1.02)
$VNB + PLAT \text{ vs } PAX + PLAT^{43,51}$	1.21 (0.85 to 1.73)	1.21 (0.85 to 1.73)	1.21 (0.85 to 1.73)	1.21 (0.85 to 1.73)
VNB + PLAT vs DOC + PLAT ^{44,52,53}	0.94 (0.78 to 1.13)	0.91 (0.75 to 1.11)	0.91 (0.75 to 1.11)	0.86 (0.71 to 1.05)
VNB + PLAT vs PEM + PLAT				
$PAX + PLAT vs DOC + PLAT^{47}$	0.97 (0.75 to 1.24)	0.97 (0.75 to 1.24)	0.97 (0.75 to 1.24)	0.97 (0.75 to 1.24)
PAX + PLAT vs PEM + PLAT				
DOC + PLAT vs PEM + PLAT				

A HR >1 favours the reference treatment and a HR <1 favours the comparator treatment.